Abitbol H, Califano J E, Abate C, Beilis P, Castellanos H
Am Heart J. 1983 Feb;105(2):227-30. doi: 10.1016/0002-8703(83)90518-5.
Flecainide acetate, a new benzamide antiarrhythmic agent, was studied after single-dose intravenous administration to 35 male and female patients with nonlife-threatening premature ventricular contractions (PVCs). Prior Holter monitoring established that each patient had "stable" PVCs of at least 600/12 hr. PCV in 80% of the patients was attributed to underlying coronary heart disease and/or Chagas' disease. After bolus injections of flecainide acetate, cardiac rhythm was again monitored by Holter ECG recording for 24 hours. All patients had 100% suppression of PVCs, ranging from 60 to 1440 minutes in duration. The average duration of suppression for all patients was more than 8 hours (498 minutes). Follow-up at 6, 12, 18, and 24 hours showed statistically significant PVC reductions (p less than 0.01) when compared with control rates. Side effects were trivial. The extended half-life of this new agent (about 20 hours in cardiac patients) may allow a convenient twice-daily dosage schedule.
对35例患有非危及生命的室性早搏（PVCs）的男性和女性患者单次静脉注射新型苯甲酰胺抗心律失常药醋酸氟卡尼后进行了研究。之前的动态心电图监测确定，每位患者的PVCs “稳定”，至少每12小时出现600次。80%患者的PVCs归因于潜在的冠心病和/或恰加斯病。静脉推注醋酸氟卡尼后，再次通过动态心电图记录监测心律24小时。所有患者的PVCs均被100%抑制，抑制持续时间为60至1440分钟。所有患者的平均抑制持续时间超过8小时（498分钟）。与对照率相比，在6、12、18和24小时的随访显示PVCs有统计学意义的减少（p<0.01）。副作用轻微。这种新药的半衰期延长（心脏病患者约为20小时），可能允许采用方便的每日两次给药方案。
